Grant: DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
University of Calgary
$120,000.00
Investigating the therapeutic potential of CD4-targeted CAR-double negative T cells in acute myeloid leukemia
FY 2025-26
Summary
Acute myeloid leukemia (AML) is an aggressive blood cancer with very poor survival rates. Standard treatments like chemotherapy often fail, and many patients relapse, leading to limited long-term survival. Bone marrow or stem cell transplants from healthy donors can sometimes cure AML by enabling the donor's immune system to attack leukemia cells. However, this approach carries major risks: if the immune attack is too weak, the leukemia returns (relapse); if it is too strong, it causes a serious complication called graft-versus-host disease (GvHD), in which donor cells attack the patient's healthy tissues.
My research focuses on a unique type of immune cell called double-negative T cells (DNTs). These cells naturally recognize and kill leukemia with minimal side effects, and our team has already demonstrated that they can be safely expanded from healthy donors and administered to patients in an early clinical trial. However, in some cases, DNTs alone are not potent enough to fully eliminate AML.
To overcome this, I am enhancing DNTs by engineering them with a special receptor called a chimeric antigen receptor (CAR) that enables them to recognize CD4-a marker found on most AML cells but not on healthy stem cells. Importantly, AML patients with lower CD4 levels tend to live longer, suggesting that targeting CD4 could both directly destroy leukemia and reshape the immune system to improve long-term survival. To ensure safety, I am also incorporating a "safety switch" that can turn off the engineered DNTs if severe side effects occur.
By combining the natural safety of DNTs with the precision of CAR technology, this project aims to develop a next-generation, off-the-shelf cell therapy to prevent relapse and improve outcomes for AML patients in Canada and beyond.
Department
Program
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
559833
Name
Wang Shanshan
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
DT1 (Biomedical and/or Clinical Research) CGRS Doctoral
Projecttitle
Investigating the therapeutic potential of CD4-targeted CAR-double negative T cells in acute myeloid leukemia
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Keyworddelim
Acute Myeloid Leukemia; Adoptive Cellular Therapy; Animal Models; Cancer Immunology; Chimeric Antigen Receptor (Car)-T Cell Therapy; Double Negative T Cells; Immunotherapy; Novel Cancer Therapies
Abstract
Acute myeloid leukemia (AML) is an aggressive blood cancer with very poor survival rates. Standard treatments like chemotherapy often fail, and many patients relapse, leading to limited long-term survival. Bone marrow or stem cell transplants from healthy donors can sometimes cure AML by enabling the donor's immune system to attack leukemia cells. However, this approach carries major risks: if the immune attack is too weak, the leukemia returns (relapse); if it is too strong, it causes a serious complication called graft-versus-host disease (GvHD), in which donor cells attack the patient's healthy tissues.
My research focuses on a unique type of immune cell called double-negative T cells (DNTs). These cells naturally recognize and kill leukemia with minimal side effects, and our team has already demonstrated that they can be safely expanded from healthy donors and administered to patients in an early clinical trial. However, in some cases, DNTs alone are not potent enough to fully eliminate AML.
To overcome this, I am enhancing DNTs by engineering them with a special receptor called a chimeric antigen receptor (CAR) that enables them to recognize CD4-a marker found on most AML cells but not on healthy stem cells. Importantly, AML patients with lower CD4 levels tend to live longer, suggesting that targeting CD4 could both directly destroy leukemia and reshape the immune system to improve long-term survival. To ensure safety, I am also incorporating a "safety switch" that can turn off the engineered DNTs if severe side effects occur.
By combining the natural safety of DNTs with the precision of CAR technology, this project aims to develop a next-generation, off-the-shelf cell therapy to prevent relapse and improve outcomes for AML patients in Canada and beyond.
Competitiondate
202511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Wang, Shanshan
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~